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Terms and Abbreviations Used in This Publication
Acute hepatitis B Newly acquired symptomatic hepatitis B virus (HBV)
infection.
Acute hepatitis C Newly acquired symptomatic hepatitis C virus (HCV)
infection.
ALT Alanine aminotransferase, previously called SGPT.
Anti-HBc Antibody to hepatitis B core antigen.
Anti-HBe Antibody to hepatitis B e antigen.
Anti-HBs Antibody to hepatitis B surface antigen.
Anti-HCV Antibody to hepatitis C virus.
Anti-HDV Antibody to hepatitis D virus.
AST Aspartate aminotransferase, previously called SGOT.
AV Arteriovenous.
Chronic (persistent) HBV infection Persistent infection with HBV; characterized by detection
of HBsAg >6 months after newly acquired infection.
Chronic (persistent) HCV infection Persistent infection with HCV; characterized by detection
of HCV RNA >6 months after newly acquired infection.
Chronic hepatitis B Liver inflammation in patients with chronic HBV infection;
characterized by abnormal levels of liver enzymes.
Chronic hepatitis C Liver inflammation in patients with chronic HCV infection;
characterized by abnormal levels of liver enzymes.
CNS Coagulase negative staphylococci.
EIA Enzyme immunoassay.
EPA U.S. Environmental Protection Agency.
ESRD End-stage renal disease.
FDA U.S. Food and Drug Administration.
GISA Glycopeptide-resistant Staphylococcus aureus.
HBcAg Hepatitis B core antigen
HBeAg Hepatitis B e antigen.
HBsAg Hepatitis B surface antigen.
HBV Hepatitis B virus.
HBV DNA Hepatitis B virus deoxyribonucleic acid.
HCV Hepatitis C virus.
HCV RNA Hepatitis C virus ribonucleic acid.
HDV Hepatitis D virus.
HIV Human immunodeficiency virus.
Isolated anti-HBc Anti-HBc positive, HBsAg negative, and anti-HBs negative.
MRSA Methicillin-resistant Staphylococcus aureus.
NNIS National Nosocomial Infections Surveillance system.
RIBA™ Recombinant immunoblot assay.
RT-PCR Reverse transcriptase polymerase chain reaction.
SGOT Serum glutamic-oxaloacetic transaminase, now called AST.
SGPT Serum glutamic-pyruvic transaminase, now called ALT.
VISA Vancomycin-intermediate Staphylococcus aureus.
VRE Vancomycin-resistant enterococci.
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Recommendations for Preventing Transmission
of Infections Among Chronic Hemodialysis Patients
Summary
These recommendations replace previous recommendations for the
prevention of bloodborne virus infections in hemodialysis centers and provide
additional recommendations for the prevention of bacterial infections in this
setting. The recommendations in this report provide guidelines for a
comprehensive infection control program that includes a) infection control
practices specifically designed for the hemodialysis setting, including routine
serologic testing and immunization; b) surveillance; and c) training and
education. Implementation of this program in hemodialysis centers will reduce
opportunities for patient-to-patient transmission of infectious agents, directly or
indirectly via contaminated devices, equipment and supplies, environmental
surfaces, or hands of personnel. Based on available knowledge, these
recommendations were developed by CDC after consultation with staff members
from other federal agencies and specialists in the field who met in Atlanta on
October 5–6, 1999. They are summarized in the Recommendations section. This
report is intended to serve as a resource for health-care professionals, public
health officials, and organizations involved in the care of patients receiving
hemodialysis.
INTRODUCTION
The number of patients with end-stage renal disease treated by maintenance hemo-
dialysis in the United States has increased sharply during the past 30 years. In 1999,
more than 3,000 hemodialysis centers had >190,000 chronic hemodialysis patients and
>60,000 staff members (1 ). Chronic hemodialysis patients are at high risk for infection
because the process of hemodialysis requires vascular access for prolonged periods. In
an environment where multiple patients receive dialysis concurrently, repeated oppor-
tunities exist for person-to-person transmission of infectious agents, directly or indi-
rectly via contaminated devices, equipment and supplies, environmental surfaces, or
hands of personnel. Furthermore, hemodialysis patients are immunosuppressed (2 ),
which increases their susceptibility to infection, and they require frequent hospitaliza-
tions and surgery, which increases their opportunities for exposure to nosocomial in-
fections.
Historically, surveillance for infections associated with chronic hemodialysis focused
on viral hepatitis, particularly hepatitis B virus (HBV) infection. CDC began conducting
national surveillance for hemodialysis-associated hepatitis in 1972 (3,4 ). Since 1976,
this surveillance has been performed in collaboration with the Health Care Financing
Administration (HCFA) during its annual facility survey. Other hemodialysis-associated
diseases and practices not related to hepatitis have been included over the years (e.g.,
pyrogenic reactions, dialysis dementia, vascular access infections, reuse practices, van-
comycin use), and the system is continually updated to collect data regarding
hemodialysis-associated practices and diseases of current interest and
importance (5–18 ).
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Recommendations for the control of hepatitis B in hemodialysis centers were first
published in 1977 (19 ), and by 1980, their widespread implementation was associated
with a sharp reduction in incidence of HBV infection among both patients and staff
members (5 ). In 1982, hepatitis B vaccination was recommended for all susceptible
patients and staff members (20 ). However, outbreaks of both HBV and hepatitis C virus
(HCV) infections continue to occur among chronic hemodialysis patients. Epidemio-
logic investigations have indicated substantial deficiencies in recommended infection
control practices, as well as a failure to vaccinate hemodialysis patients against hepati-
tis B (21,22 ). These practices apparently are not being fully implemented because staff
members a) are not aware of the practices and their importance, b) are confused re-
garding the differences between standard (i.e., universal) precautions recommended
for all health-care settings and the additional precautions necessary in the hemodialy-
sis setting, and c) believe that hepatitis B vaccine is ineffective for preventing HBV
infection in chronic hemodialysis patients (22 ).
Bacterial infections, especially those involving vascular access, are the most fre-
quent infectious complication of hemodialysis and a major cause of morbidity and
mortality among hemodialysis patients (1 ). During the 1990s, the prevalence of anti-
microbial-resistant bacteria (e.g., methicillin-resistant Staphylococcus aureus  [MRSA]
and vancomycin-resistant enterococci [VRE]) increased rapidly in health-care settings,
including hemodialysis units (18,23 ). Although numerous outbreaks of bacterial infec-
tions in the hemodialysis setting have been reported (24 ), few studies exist regarding
the epidemiology and prevention of endemically occurring bacterial infections in he-
modialysis patients, and formal recommendations to prevent such infections have not
been published previously. In 1999, CDC initiated a surveillance system for bloodstream
and vascular access infections in outpatient hemodialysis centers to determine the fre-
quency of and risk factors for these complications in order to formulate and evaluate
strategies for control (25 ).
The recommendations contained in this report were developed by reviewing avail-
able data and are based on consultations with specialists in the field. These recommen-
dations provide guidelines for infection control strategies, unique to the hemodialysis
setting, that should be used to prevent patient-to-patient transmission of bloodborne
viruses and pathogenic bacteria. They are summarized on pages 20–21.
These recommendations do not address sources of bacterial and chemical contami-
nants in dialysis systems, water treatment or distribution, specific procedures for re-
processing dialyzers, clinical practice methods to prevent bacterial infections (e.g.,
techniques for skin preparation and access), or comprehensive strategies for prevent-
ing infections among health-care workers (see Suggested Readings for information on
these topics).
BACKGROUND
Hepatitis B Virus Infection
Epidemiology
Incidence and Prevalence. In 1974, the incidence of newly acquired (i.e., acute) HBV
infection among chronic hemodialysis patients in the United States was 6.2%, and se-
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lected hemodialysis centers reported rates as high as 30% (4 ). By 1980, nationwide
incidence among patients had decreased to 1% (5 ), and by 1999, to 0.06% (18 ) (CDC,
unpublished data, 2001), with only 3.5% of all centers reporting newly acquired infec-
tions. Prevalence of chronic HBV infection (i.e., hepatitis B surface antigen [HBsAg]
positivity) among hemodialysis patients declined from 7.8% in 1976 to 3.8% in 1980
and to 0.9% by 1999 (5,18 ) (CDC, unpublished data, 2001). In 1999, a total of 27.7% of
3,483 centers provided dialysis to >1 patient with either acute or chronic HBV infection
(CDC, unpublished data, 2001).
Transmission. HBV is transmitted by percutaneous (i.e., puncture through the skin)
or permucosal (i.e., direct contact with mucous membranes) exposure to infectious
blood or to body fluids that contain blood, and the chronically infected person is cen-
tral to the epidemiology of HBV transmission. All HBsAg-positive persons are infec-
tious, but those who are also positive for hepatitis B e antigen (HBeAg) circulate HBV at
high titers in their blood (108–9 virions/mL) (26,27 ). With virus titers in blood this high,
body fluids containing serum or blood also can contain high levels of HBV and are
potentially infectious. Furthermore, HBV at titers of 102–3 virions/mL can be present on
environmental surfaces in the absence of any visible blood and still result in
transmission (28,29 ).
HBV is relatively stable in the environment and remains viable for at least 7 days on
environmental surfaces at room temperature (29 ). HBsAg has been detected in dialy-
sis centers on clamps, scissors, dialysis machine control knobs, and doorknobs (30 ).
Thus, blood-contaminated surfaces that are not routinely cleaned and disinfected rep-
resent a reservoir for HBV transmission. Dialysis staff members can transfer virus to
patients from contaminated surfaces by their hands or gloves or through use of con-
taminated equipment and supplies (30 ).
Most HBV infection outbreaks among hemodialysis patients were caused by cross-
contamination to patients via a) environmental surfaces, supplies (e.g., hemostats,
clamps), or equipment that were not routinely disinfected after each use; b) multiple
dose medication vials and intravenous solutions that were not used exclusively for one
patient; c) medications for injection that were prepared in areas adjacent to areas where
blood samples were handled; and d) staff members who simultaneously cared for both
HBV-infected and susceptible patients (21,31–35 ). Once the factors that promote HBV
transmission among hemodialysis patients were identified, recommendations for con-
trol were published in 1977 (19 ). These recommendations included a) serologic sur-
veillance of patients (and staff members) for HBV infection, including monthly testing
of all susceptible patients for HBsAg; b) isolation of HBsAg-positive patients in a sepa-
rate room; c) assignment of staff members to HBsAg-positive patients and not to HBV-
susceptible patients during the same shift; d) assignment of dialysis equipment to
HBsAg-positive patients that is not shared by HBV-susceptible patients; e) assignment
of a supply tray to each patient (regardless of serologic status); f) cleaning and disinfec-
tion of nondisposable items (e.g., clamps, scissors) before use on another patient; g)
glove use whenever any patient or hemodialysis equipment is touched and glove
changes between each patient (and station); and h) routine cleaning and disinfection of
equipment and environmental surfaces.
The segregation of HBsAg-positive patients and their equipment from HBV-
susceptible patients resulted in 70%–80% reductions in incidence of HBV infection
among hemodialysis patients (7,36–38 ). National surveillance data for 1976–1989 indi-
cated that incidence of HBV infection was substantially lower in hemodialysis units
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that isolated HBsAg-positive patients, compared with those that did not (7,10 ). The
success of isolation practices in preventing transmission of HBV infection is linked to
other infection control practices, including routine serological surveillance and routine
cleaning and disinfection. Frequent serologic testing for HBsAg detects patients re-
cently infected with HBV quickly so isolation procedures can be implemented before
cross-contamination can occur. Environmental control by routine cleaning and disin-
fection procedures reduces the opportunity for cross-contamination, either directly from
environmental surfaces or indirectly by hands of personnel.
Despite the current low incidence of HBV infection among hemodialysis patients,
outbreaks continue to occur in chronic hemodialysis centers. Investigations of these
outbreaks have documented that HBV transmission resulted from failure to use recom-
mended infection control practices, including a) failure to routinely screen patients for
HBsAg or routinely review results of testing to identify infected patients; b) assignment
of staff members to the simultaneous care of infected and susceptible patients; and c)
sharing of supplies, particularly multiple dose medication vials, among patients (21 ).
In addition, few patients had received hepatitis B vaccine (21 ). National surveillance
data have demonstrated that independent risk factors among chronic hemodialysis
patients for acquiring HBV infection include the presence of >1 HBV-infected patient in
the hemodialysis center who is not isolated, as well as a <50% hepatitis B vaccination
rate among patients (15 ).
HBV infection among chronic hemodialysis patients also has been associated with
hemodialysis provided in the acute-care setting (21,39 ). Transmission appeared to stem
from chronically infected HBV patients who shared staff members, multiple dose medi-
cation vials, and other supplies and equipment with susceptible patients. These epi-
sodes were recognized when patients returned to their chronic hemodialysis units, and
routine HBsAg testing was resumed. Transmission from HBV-infected chronic hemodi-
alysis patients to patients undergoing hemodialysis for acute renal failure has not been
documented, possibly because these patients are dialyzed for short durations and have
limited exposure. However, such transmission could go unrecognized because acute
renal failure patients are unlikely to be tested for HBV infection.
Clinical Features and Natural History
HBV causes both acute and chronic hepatitis. The incubation period ranges from
45–160 days (mean: 120 days), and the onset of acute disease is usually insidious. In-
fants, young children (aged <10 years), and immunosuppressed adults with newly ac-
quired HBV infection are usually asymptomatic (40 ). When present, clinical symptoms
and signs might include anorexia, malaise, nausea, vomiting, abdominal pain, and jaun-
dice. Extrahepatic manifestations of disease (e.g., skin rashes, arthralgias, and arthritis)
can also occur (41 ). The case fatality rate after acute hepatitis B is 0.5%–1%.
In adults with normal immune status, most (94%–98%) recover completely from
newly acquired HBV infections, eliminating virus from the blood and producing neu-
tralizing antibody that creates immunity from future infection (40,42 ). In immunosup-
pressed persons (including hemodialysis patients), infants, and young children, most
newly acquired HBV infections result in chronic infection. Although the consequences
of acute hepatitis B can be severe, most of the serious sequelae associated with the
disease occur in persons in whom chronic infection develops. Although persons with
chronic HBV infection are often asymptomatic, chronic liver disease develops in two-
Vol. 50 / No. RR-5 MMWR 5
thirds of these persons, and approximately 15%–25% die prematurely from cirrhosis or
liver cancer (43–45 ).
Subtypes of HBV exist, and infection or immunization with one subtype confers
immunity to all subtypes. However, reinfection or reactivation of latent HBV infection
has been reported among certain groups of immunosuppressed patients, including
those who have undergone renal transplant and those infected with human immuno-
deficiency virus (HIV) (46,47 ). These patients were positive for antibody to hepatitis B
core antigen (anti-HBc), with or without antibody to HBsAg (anti-HBs), and subsequently
developed detectable levels of HBsAg. The frequency with which this occurs is un-
known.
Monotherapy with alpha interferon or lamivudine is approved by the U.S. Food and
Drug Administration (FDA) to treat patients with chronic hepatitis B (48,49 ). Although
the dosage of lamivudine should be modified based on creatinine clearance in patients
with renal impairment, no additional dose modification is necessary after routine he-
modialysis. The emergence of lamivudine-resistant variants has caused concern re-
garding long-term use of this drug.
Screening and Diagnostic Tests
Serologic Assays. Several well-defined antigen-antibody systems are associated
with HBV infection, including HBsAg and anti-HBs; hepatitis B core antigen (HBcAg)
and anti-HBc; and HBeAg and antibody to HBeAg (anti-HBe). Serologic assays are com-
mercially available for all of these except HBcAg because no free HBcAg circulates in
blood. One or more of these serologic markers are present during different phases of
HBV infection (Table 1) (42 ).
TABLE 1. Interpretation of serologic test results for hepatitis B virus infection
Serologic Markers Interpretation
HBsAg* Total IgM§ Anti-HBs¶
Anti-HBc† Anti-HBc
– – – – Susceptible, never infected
+ – – – Acute infection, early
incubation**
+ + + – Acute infection
– + + – Acute resolving infection
– + – + Past infection, recovered
and immune
+ + – – Chronic infection
– + – – False positive (i.e., susceptible),
past infection, or “low-level”
chronic infection
– – – + Immune if titer is >10 mIU/mL
* Hepatitis B surface antigen.
† Antibody to hepatitis B core antigen.
§ Immunoglobulin M.
¶ Antibody to hepatitis B surface antigen.
**Transient HBsAg positivity (lasting <18 days) might be detected in some patients during
vaccination.
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The presence of HBsAg is indicative of ongoing HBV infection and potential infec-
tiousness. In newly infected persons, HBsAg is present in serum 30–60 days after expo-
sure to HBV and persists for variable periods. Transient HBsAg positivity (lasting <18
days) can be detected in some patients during vaccination (50,51 ). Anti-HBc develops
in all HBV infections, appearing at onset of symptoms or liver test abnormalities in
acute HBV infection, rising rapidly to high levels, and persisting for life. Acute or re-
cently acquired infection can be distinguished by presence of the immunoglobulin M
(IgM) class of anti-HBc, which persists for approximately 6 months.
In persons who recover from HBV infection, HBsAg is eliminated from the blood,
usually in 2–3 months, and anti-HBs develops during convalescence. The presence of
anti-HBs indicates immunity from HBV infection. After recovery from natural infection,
most persons will be positive for both anti-HBs and anti-HBc, whereas only anti-HBs
develops in persons who are successfully vaccinated against hepatitis B. Persons who
do not recover from HBV infection and become chronically infected remain positive for
HBsAg (and anti-HBc), although a small proportion (0.3% per year) eventually clear
HBsAg and might develop anti-HBs (45 ).
In some persons, the only HBV serologic marker detected is anti-HBc (i.e., isolated
anti-HBc). Among most asymptomatic persons in the United States tested for HBV in-
fection, an average of 2% (range: <0.1%–6%) test positive for isolated anti-HBc (52 );
among injecting-drug users, however, the rate is 24% (53 ). In general, the frequency of
isolated anti-HBc is directly related to the frequency of previous HBV infection in the
population and can have several explanations. This pattern can occur after HBV infec-
tion among persons who have recovered but whose anti-HBs levels have waned or
among persons who failed to develop anti-HBs. Persons in the latter category include
those who circulate HBsAg at levels not detectable by current commercial assays. How-
ever, HBV DNA has been detected in <10% of persons with isolated anti-HBc, and these
persons are unlikely to be infectious to others except under unusual circumstances
involving direct percutaneous exposure to large quantities of blood (e.g., transfusion)
(54 ). In most persons with isolated anti-HBc, the result appears to be a false positive.
Data from several studies have demonstrated that a primary anti-HBs response devel-
ops in most of these persons after a three-dose series of hepatitis B vaccine (55,56 ). No
data exist on response to vaccination among hemodialysis patients with this serologic
pattern.
A third antigen, HBeAg, can be detected in serum of persons with acute or chronic
HBV infection. The presence of HBeAg correlates with viral replication and high levels
of virus (i.e., high infectivity). Anti-HBe correlates with the loss of replicating virus and
with lower levels of virus. However, all HBsAg-positive persons should be considered
potentially infectious, regardless of their HBeAg or anti-HBe status.
Nucleic Acid Detection. HBV infection can be detected using qualitative or quantita-
tive tests for HBV DNA. These tests are not FDA-approved and are most commonly
used for patients being managed with antiviral therapy (49,57 ).
Hepatitis B Vaccine
Hepatitis B vaccine has been recommended for both hemodialysis patients and staff
members since the vaccine became available in 1982 (20 ). By 1999, a total of 55% of
patients and 88% of staff members had been vaccinated (18 ) (CDC, unpublished data,
2001). Two types of vaccine have been licensed and used in the United States: plasma-
derived and recombinant. Plasma-derived vaccine is no longer available in the United
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States, but is produced in several countries and used in many immunization programs
worldwide. Recombinant vaccines available in the United States are Recombivax HB™
(Merck & Company, Inc., West Point, Pennsylvania) and Engerix-B® (SmithKline
Beecham Biologicals, Philadelphia, Pennsylvania). Recombivax HB™ contains 10–40
µg of HBsAg protein per mL, whereas Engerix-B® contains 20 µg/mL.
Primary vaccination comprises three intramuscular doses of vaccine, with the sec-
ond and third doses given 1 and 6 months, respectively, after the first. An alternative
schedule of four doses given at 0, 1, 2, and 12 months to persons with normal immune
status or at 0, 1, 2, and 6 months to hemodialysis patients has been approved for
Engerix-B®.
Immunogenicity. The recommended primary series of hepatitis B vaccine induces a
protective anti-HBs response (defined as >10 milli-International Units [mIU]/mL) in 90%–
95% of adults with normal immune status. The major determinant of vaccine response
is age, with the proportion of persons developing a protective antibody response de-
clining to 84% among adults aged >40 years and to 75% by age 60 years (58,59 ). Other
host factors that contribute to decreased immunogenicity include smoking, obesity,
and immune suppression. Compared with adults with normal immune status, the pro-
portion of hemodialysis patients who develop a protective antibody response after
vaccination (with higher dosages) is lower. For those who receive the three-dose sched-
ule, the median is 64% (range: 34%–88%) (60–65 ), and for those who receive the four-
dose schedule, the median is 86% (range: 40%–98%) (66–72 ). Limited data indicate
that concurrent infection with HCV does not interfere with development of protective
levels of antibody after vaccination, although lower titers of anti-HBs have been re-
ported after vaccination of HCV-positive patients compared with HCV-negative patients
(65,73–75 ).
Some studies have demonstrated that higher antibody response rates could be
achieved by vaccinating patients with chronic renal failure before they become dialysis
dependent, particularly patients with mild or moderate renal failure. After vaccination
with four 20 µg doses of recombinant vaccine, a protective antibody response devel-
oped in 86% of predialysis adult patients with serum creatinine levels <4.0 mg/dl (mean:
2.0 mg/dl) compared with 37% of those with serum creatinine levels >4.0 mg/dl (mean:
9.5 mg/dl), only 12% of whom were predialysis patients (76 ). In an earlier study, a
lower response to recombinant vaccine among predialysis patients was reported, pos-
sibly because patients with more severe renal failure were included (77,78 ).
Although no data exist on the response of pediatric hemodialysis patients to vacci-
nation with standard pediatric doses, 75%–97% of those who received higher dosages
(20 µg) on either the three- or four-dose schedule developed protective levels of anti-
HBs (79–81 ). In the one study that evaluated vaccine response among children with
chronic renal failure before they became dialysis dependent, high response rates were
achieved after four-20 µg doses in both predialysis and dialysis-dependent patients,
although predialysis patients had higher peak antibody titers (82 ).
Vaccine Efficacy. For persons with normal immune status, controlled clinical trials
have demonstrated that protection from acute and chronic HBV infection is virtually
complete among those who develop a protective antibody response after vaccination
(83,84 ). Among hemodialysis patients, controlled clinical trials conducted in other coun-
tries demonstrated efficacy of 53%–78% after preexposure immunization (85,86 ). How-
ever, no efficacy was demonstrated in the one trial performed in the United States (62 ).
When the latter trial was designed, the sample size was calculated based on an annual
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incidence rate among susceptible patients of 13.8% (i.e., the rate observed during 1976–
1979, the period before the start of the trial). However, by the time the trial was con-
ducted, the incidence rate had declined by >60%, and the sample size was inadequate
for detecting a difference in infection rates between vaccinated and placebo groups.
Although efficacy was not demonstrated in this study, no infections occurred among
persons who developed and maintained protective levels of anti-HBs.
Furthermore, since the hepatitis B vaccine became available, no HBV infections have
been reported among vaccinated hemodialysis patients who maintained protective lev-
els of anti-HBs. This observation has been particularly striking during HBV infection
outbreaks in this setting (21 ). In addition, a case-control study indicated that the risk for
HBV infection was 70% lower among hemodialysis patients who had been vaccinated
(87 ). Thus, most hemodialysis patients can be protected from hepatitis B by vaccina-
tion, and maintaining immunity among these patients reduces the frequency and costs
of serologic screening (88 ).
Revaccination of Nonresponders. Among persons who do not respond to the pri-
mary three-dose series of hepatitis B vaccine, 25%–50% of those with normal immune
status respond to one additional vaccine dose, and 50%–75% respond to three addi-
tional doses (59,84 ). A revaccination regimen that includes serologic testing after one
or two additional doses of vaccine appears to be no more cost-effective than serologic
testing performed after all three additional doses (89 ). For persons found to be
nonresponders after six doses of vaccine, no data exist to indicate that additional doses
would induce an antibody response. Few studies have been conducted of the effect of
revaccination among hemodialysis patients who do not respond to the primary vac-
cine series. Response rates to revaccination varied from 40%–50% after two or three
additional 40 µg intramuscular doses to 64% after four additional 10 µg intramuscular
doses (69,70,90–94 ).
Antibody Persistence. Among adults with normal immune status who responded to
a primary vaccine series with a protective antibody level, antibody remained above
protective levels in 40%–87% of persons after 9–15 years (95–98 ). Only short-term data
are available for hemodialysis patients. Among adults who responded to the primary
vaccination series, antibody remained detectable for 6 months in 80%–100% (median:
100%) of persons and for 12 months in 58%–100% (median: 70%) (61,64–69,71,85,99–
103 ). Among successfully immunized hemodialysis patients whose antibody titers sub-
sequently declined below protective levels, limited data indicate that virtually all
respond to a booster dose (75 ).
Duration of Vaccine-Induced Immunity. Among persons with normal immune sta-
tus who respond to the primary series of hepatitis B vaccine, protection against hepati-
tis B persists even when antibody titers become undetectable (97 ). However, among
hemodialysis patients who respond to the vaccine, protection against hepatitis B is not
maintained when antibody titers fall below protective levels. In the U.S. vaccine effi-
cacy trial, three hemodialysis patients who responded to the primary vaccination series
developed HBV infection (62 ). One had received a kidney transplant 6 months before
onset of infection, and anti-HBs had declined to borderline protective levels in the other
two persons. In all three patients, infection resolved.
Alternative Routes of Administration. Among adults with normal immune status,
intradermal administration of low doses of hepatitis B vaccine results in lower
seroconversion rates (55%–81%) (104–106 ), and no data exist on long-term protection
from this route of administration. Among infants and children, intradermal vaccination
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results in poor immunogenicity. Data are insufficient to evaluate alternative routes (e.g.,
intradermal) for vaccination among hemodialysis patients.
Hepatitis C Virus Infection
Epidemiology
Incidence and Prevalence. Data are limited on incidence of HCV infection among
chronic hemodialysis patients. During 1982–1997, the incidence of non-A, non-B hepa-
titis among patients reported to CDC’s national surveillance system decreased from
1.7% to 0.2% (18 ). The validity of these rates is uncertain because of inherent difficul-
ties in diagnosing non-A, non-B hepatitis and probable variability in the application of
diagnostic criteria by different dialysis centers. However, the downward trend can par-
tially be explained by a decline in the rate of transfusion-associated disease after
1985 (107,108 ).
Since 1990, limited data from U.S. studies using testing for antibody to HCV (anti-
HCV) to evaluate the incidence of HCV infection have reported annual rates of 0.73%–
3% among hemodialysis patients (109,110 ). None of the patients who seroconverted
had received transfusions in the interim or were injecting-drug users.
During 1992–1999, national surveillance data indicated that the proportion of cen-
ters that tested patients for anti-HCV increased from 22% to 56% (18 ) (CDC, unpub-
lished data, 2001). In 1999, nationwide prevalence of anti-HCV was 8.9%, with some
centers reporting prevalences >40% (CDC, unpublished data, 2001). Other studies of
hemodialysis patients in the United States have reported anti-HCV prevalences of 10%–
36% among adults (109,111,112 ) and 18.5% among children (113 ).
Transmission. HCV is most efficiently transmitted by direct percutaneous exposure
to infectious blood, and like HBV, the chronically infected person is central to the epide-
miology of HCV transmission. Risk factors associated with HCV infection among hemo-
dialysis patients include history of blood transfusions, the volume of blood transfused,
and years on dialysis (114 ). The number of years on dialysis is the major risk factor
independently associated with higher rates of HCV infection. As the time patients spent
on dialysis increased, their prevalence of HCV infection increased from an average of
12% for patients receiving dialysis <5 years to an average of 37% for patients receiving
dialysis >5 years (109,112,115 ).
These studies, as well as investigations of dialysis-associated outbreaks of hepatitis
C, indicate that HCV transmission most likely occurs because of inadequate infection
control practices. During 1999–2000, CDC investigated three outbreaks of HCV infection
among patients in chronic hemodialysis centers (CDC, unpublished data, 1999 and
2000). In two of the outbreaks, multiple transmissions of HCV occurred during periods
of 16–24 months (attack rates: 6.6%–17.5%), and seroconversions were associated with
receiving dialysis immediately after a chronically infected patient. Multiple opportuni-
ties for cross-contamination among patients were observed, including a) equipment
and supplies that were not disinfected between patient use; b) use of common medica-
tion carts to prepare and distribute medications at patients’ stations; c) sharing of mul-
tiple dose medication vials, which were placed at patients’ stations on top of
hemodialysis machines; d) contaminated priming buckets that were not routinely
changed or cleaned and disinfected between patients; e) machine surfaces that were
not routinely cleaned and disinfected between patients; and f) blood spills that were
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not cleaned up promptly. In the third outbreak, multiple new infections clustered at one
point in time (attack rate: 27%), suggesting a common exposure event. Although the
specific results of this investigation are pending, multiple opportunities for cross-
contamination from chronically infected patients also were observed in this unit. In
particular, supply carts were moved from one station to another and contained both
clean supplies and blood-contaminated items, including small biohazard containers,
sharps disposal boxes, and used vacutainers containing patients’ blood.
Clinical Features and Natural History
HCV causes both acute and chronic hepatitis. The incubation period ranges from
14–180 days (average: 6–7 weeks) (116 ). Persons with newly acquired (acute) HCV in-
fection typically are either asymptomatic or have a mild clinical illness. The course of
acute hepatitis C is variable, although elevations in serum alanine aminotransferase
(ALT) levels, often in a fluctuating pattern, are the most characteristic feature. Fulmi-
nant hepatic failure after acute hepatitis C is rare.
Most (average: 94%) hemodialysis patients with newly acquired HCV infection have
elevated serum ALT levels (117–121 ). Elevations in serum ALT levels often precede
anti-HCV seroconversion. Among prospectively followed transfusion recipients who
developed acute HCV infection, elevated ALT levels preceded anti-HCV seroconversion
(as measured by second generation assays) in 59%, and anti-HCV was detectable in
most patients (78%) within 5 weeks after their first ALT elevation (122 ). However, eleva-
tions in ALT or aspartate aminotransferase (AST) levels can occur that are not related to
viral hepatitis, and compared with ALT, AST is a less specific indicator of HCV-related
liver disease among hemodialysis patients. In a recent outbreak investigation, only
28% of 25 hemodialysis patients with newly observed elevations in AST levels tested
anti-HCV positive (CDC, unpublished data, 1999).
After acute HCV infection, 15%–25% of persons with normal immune status appear
to resolve their infection without sequelae as defined by sustained absence of HCV
RNA in serum and normalization of ALT (123 ). In some persons, ALT levels normalize,
suggesting full recovery, but this is frequently followed by ALT elevations that indicate
progression to chronic disease. Chronic HCV infection develops in most infected per-
sons (75%–85%). Of persons with chronic HCV infection, 60%–70% have persistent or
fluctuating ALT elevations, indicating active liver disease (123 ). Although similar rates
of chronic liver disease have been observed among HCV-infected chronic hemodialysis
patients (based on liver biopsy results), these patients might be less likely to have bio-
chemical evidence of active liver disease (124 ). In seroprevalence studies of chronic
hemodialysis patients, ALT elevations were reported in a median of 33.9% (range: 6%–
73%) of patients who tested positive for anti-HCV (117,124–136 ).
No clinical or epidemiologic features among patients with acute infection have been
reported to be predictive of either persistent infection or chronic liver disease. Most
studies have reported that cirrhosis develops in 10%–20% of persons who have had
chronic hepatitis C for 20–30 years, and hepatocellular carcinoma in 1%–5% (123 ). Ex-
trahepatic manifestations of chronic HCV infection are considered to be of immuno-
logic origin and include cryoglobulinemia, membranoproliferative glomerulonephritis,
and porphyria cutanea tarda (137 ).
At least six different genotypes and >90 subtypes of HCV exist, with genotype 1
being the most common in the United States (138,139 ). Unlike HBV, infection with one
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HCV genotype or subtype does not protect against reinfection or superinfection with
other HCV strains (139 ).
Alpha interferon alone or in combination with ribavirin is FDA-approved for the
treatment of chronic hepatitis C (48,140,141 ). Combination therapy should be used
with caution in patients with creatinine clearance <50 mL/minute and generally is con-
traindicated in patients with renal failure (141,142 ). Interferon monotherapy results in
low sustained virologic response rates (141,142 ).
Screening and Diagnostic Tests
Serologic Assays. The only FDA-approved tests for diagnosis of HCV infection are
those that measure anti-HCV and include enzyme immunoassays (EIAs) and a supple-
mental recombinant immunoblot assay (RIBA™) (116 ). These tests detect anti-HCV in
>97% of infected persons, but do not distinguish between acute, chronic, or resolved
infection. The average time from exposure to seroconversion is 8–9 weeks (122 ). Anti-
HCV can be detected in 80% of patients within 15 weeks after exposure, in >90% within
5 months, and in >97% within 6 months (122,143 ). In rare instances, seroconversion
can be delayed until 9 months after exposure (143,144 ). Anti-HCV persists indefinitely
in most persons, but does not protect against reinfection.
As with any screening test, the positive predictive value of EIAs for anti-HCV is
directly related to the prevalence of infection in the population and is low in popula-
tions with an HCV-infection prevalence <10% (145,146 ). Supplemental testing with a
more specific assay (i.e., RIBA™) of a specimen with a positive anti-HCV result by EIA
prevents reporting of false-positive results, particularly in settings where asymptom-
atic persons are being tested. Results of seroprevalence studies among chronic hemo-
dialysis patients have indicated that 57%–100% of EIA positive results were RIBA™
positive (124,126,128,133,135,147–152 ), and 53%–100% were HCV RNA positive by re-
verse transcriptase polymerase chain reaction (RT-PCR) testing (117,127,129,134,135 ).
Nucleic Acid Detection. The diagnosis of HCV infection also can be made by quali-
tatively detecting HCV RNA using gene amplification techniques (e.g., RT-PCR) (116 ).
HCV RNA can be detected in serum or plasma within 1–2 weeks after exposure and
weeks before onset of ALT elevations or the appearance of anti-HCV. In rare instances,
detection of HCV RNA might be the only evidence of HCV infection. Although a median
of 3.4% (range: 0%–28%) of chronic hemodialysis patients who tested anti-HCV nega-
tive were HCV RNA positive, this might be an overestimate because follow-up samples
to detect possible antibody seroconversions were not obtained on these patients
(117,118,126–128,130,131,133,134,148–154 ).
Although not FDA-approved, RT-PCR assays for HCV infection are used commonly
in clinical practice and are commercially available. Most RT-PCR assays have a lower
limit of detection of 100–1,000 viral genome copies per mL. With adequate optimiza-
tion of RT-PCR assays, 75%–85% of persons who are positive for anti-HCV and >95% of
persons with acute or chronic hepatitis C will test positive for HCV RNA. Some HCV-
infected persons might be only intermittently HCV RNA positive, particularly those
with acute hepatitis C or with end-stage liver disease caused by hepatitis C. To mini-
mize false-negative results, blood samples collected for RT-PCR should not contain
heparin, and serum must be separated from cellular components within 2–4 hours
after collection and preferably stored frozen at -20 C or -70 C (155 ). If shipping is re-
quired, frozen samples should be protected from thawing. Because of assay variability,
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rigorous quality assurance and control should be in place in clinical laboratories per-
forming this assay, and proficiency testing is recommended.
Quantitative assays for measuring the concentration (i.e., titer) of HCV RNA have
been developed and are available from commercial laboratories (156 ). These assays
also are not FDA-approved and are less sensitive than qualitative RT-PCR assays (157 ).
Quantitative assays should not be used as a primary test to confirm or exclude the
diagnosis of HCV infection or to monitor the endpoint of treatment, and sequential
measurement of HCV RNA levels has not proven useful in managing patients with
hepatitis C.
Other Bloodborne Viruses
Hepatitis Delta Virus Infection
Delta hepatitis is caused by the hepatitis delta virus (HDV), a defective virus that
causes infection only in persons with active HBV infection. The prevalence of HDV in-
fection is low in the United States, with rates of <1% among HBsAg-positive persons in
the general population and >10% among HBsAg-positive persons with repeated percu-
taneous exposures (e.g., injecting-drug users, persons with hemophilia) (158 ). Areas
of the world with high endemic rates of HDV infection include southern Italy, parts of
Africa, and the Amazon Basin.
Few data exist on the prevalence of HDV infection among chronic hemodialysis
patients, and only one transmission of HDV between such patients has been reported
in the United States (159 ). In this episode, transmission occurred from a patient who
was chronically infected with HBV and HDV to an HBsAg-positive patient after a mas-
sive bleeding incident; both patients received dialysis at the same station.
HDV infection occurs either as a co-infection with HBV or as a superinfection in a
person with chronic HBV infection. Co-infection usually resolves, but superinfection
frequently results in chronic HDV infection and severe disease. High mortality rates are
associated with both types of infection. A serologic test that measures total antibody to
HDV (anti-HDV) is commercially available.
Human Immunodeficiency Virus Infection
During 1985–1999, the percentage of U.S. hemodialysis centers that reported pro-
viding chronic hemodialysis for patients with HIV infection increased from 11% to 39%,
and the proportion of hemodialysis patients with known HIV infection increased from
0.3% to 1.4% (18 ) (CDC, unpublished data, 2001).
HIV is transmitted by blood and other body fluids that contain blood. No patient-to-
patient transmission of HIV has been reported in U.S. hemodialysis centers. However,
such transmission has been reported in other countries; in one case, HIV transmission
was attributed to mixing of reused access needles and inadequate disinfection of equip-
ment (160 ).
HIV infection is usually diagnosed with assays that measure antibody to HIV, and a
repeatedly positive EIA test should be confirmed by Western blot or another confirma-
tory test. Antiretroviral therapies for HIV-infected hemodialysis patients are commonly
used and appear to be improving survival rates among this population. However, hepa-
totoxicity associated with certain protease inhibitors might limit the use of these drugs,
especially in patients with underlying liver dysfunction (161 ).
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Bacterial Infections
Epidemiology
Disease Burden. The annual mortality rate among hemodialysis patients is 23%,
and infections are the second most common cause, accounting for 15% of deaths (1 ).
Septicemia (10.9% of all deaths) is the most common infectious cause of mortality. In
various studies evaluating rates of bacterial infections in hemodialysis outpatients,
bacteremia occurred in 0.63%–1.7% of patients per month and vascular access infec-
tions (with or without bacteremia) in 1.3%–7.2% of patients per month (162–170 ). Na-
tional surveillance data indicated that 4%–5% of patients received intravenous
vancomycin during a 1-month period (and additional patients received other antimi-
crobials) (18 ). Although data on vancomycin use can be used to derive an estimate of
the prevalence of suspected infections, the proportion of patients receiving antimicro-
bials who would fit a formal case definition for bacterial infection is unknown.
Infection Sites. In a study of 27 French hemodialysis centers, 28% of 230 infections
in hemodialysis patients involved the vascular access, whereas 25% involved the lung,
23% the urinary tract, 9% the skin and soft tissues, and 15% other or unknown sites
(165 ). Thirty-three percent of infections involved either the vascular access site or were
bacteremias of unknown origin, many of which might have been caused by occult ac-
cess infections. Thus, the vascular access site was the most common site for infection,
but accounted for only one-third of infections. However, access site infections are par-
ticularly important because they can cause disseminated bacteremia or loss of the vas-
cular access.
Vascular Access Infections. Vascular access infections are caused (in descending
order of frequency) by S. aureus, coagulase-negative staphylococci (CNS), gram-
negative bacilli, nonstaphylococcal gram-positive cocci (including enterococci), and
fungi (171 ). The proportion of infections caused by CNS is higher among patients dia-
lyzed through catheters than among patients dialyzed through fistulas or grafts.
The primary risk factor for access infection is access type, with catheters having the
highest risk for infection, grafts intermediate, and native arteriovenous (AV) fistulas the
lowest (168 ). Other potential risk factors for vascular access infections include a) loca-
tion of the access in the lower extremity; b) recent access surgery; c) trauma, hematoma,
dermatitis, or scratching over the access site; d) poor patient hygiene; e) poor needle
insertion technique; f) older age; g) diabetes; h) immunosuppression; and i) iron over-
load (164,167,172–175 ).
Transmission. Bacterial pathogens causing infection can be either exogenous (i.e,
acquired from contaminated dialysis fluids or equipment) or endogenous (i.e., caused
by invasion of bacteria present in or on the patient). Exogenous pathogens have caused
numerous outbreaks, most of which resulted from inadequate dialyzer reprocessing
procedures (e.g., contaminated water or inadequate disinfectant) or inadequate treat-
ment of municipal water for use in dialysis. During 1995–1997, four outbreaks were
traced to contamination of the waste drain port on one type of dialysis machine (176 ).
Recommendations to prevent such outbreaks are published elsewhere (171 ).
Contaminated medication vials also are a potential source of bacterial infection for
patients. In 1999, an outbreak of Serratia liquefaciens bloodstream infections and pyro-
genic reactions among hemodialysis patients was traced to contamination of vials of
erythropoietin. These vials, which were intended for single use, were contaminated by
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repeated puncture to obtain additional doses and by pooling of residual medication
into a common vial (177 ).
Endogenous pathogens first colonize the patient and later cause infection. Coloniza-
tion means that microorganisms have become resident in or on the body (e.g., in the
nares or stool); a culture from the site is positive, but no symptoms or signs of infection
exist. Colonization with potentially pathogenic microorganisms, often unknown to staff
members, is common in patients with frequent exposure to hospitals and other health-
care settings. Colonization most often occurs when microorganisms are transmitted
from a colonized or infected source patient to another patient on the hands of health-
care workers who do not comply with infection control precautions. Less commonly,
contamination of environmental surfaces (e.g., bed rails, countertops) plays a role (178 ).
Infection occurs when microorganisms invade the body, damaging tissue and caus-
ing signs or symptoms of infection, and is aided by invasive devices (e.g., the hemodi-
alysis vascular access). Evidence exists that when prevalence of colonization in a
population is less frequent, infection in that population will also be less frequent, and
infection control recommendations for hemodialysis units are designed to prevent colo-
nization (179 ). Additional measures designed to prevent infection from colonizing or-
ganisms (e.g., using aseptic technique during vascular access) are presented
elsewhere (180 ).
Antimicrobial Resistance
Antimicrobial-resistant bacteria are more common in patients with severe illness,
who often have had multiple hospitalizations or surgical procedures, and in those who
have received prolonged courses of antimicrobial agents. In health-care settings, in-
cluding hemodialysis centers, such patients can serve as a source for transmission.
Clinically important drug-resistant bacteria that commonly cause health-care–
associated infections include MRSA, methicillin-resistant CNS, VRE, and multidrug-
resistant gram negative rods, including strains of Pseudomonas aeruginosa,
Stenotrophomonas maltophilia, and Acinetobacter species, some of which are resis-
tant to all available antimicrobials. In addition, strains of S. aureus with intermediate
resistance to vancomycin and other glycopeptide antibiotics have recently been re-
ported; these strains are called vancomycin-intermediate S. aureus  (VISA) or glyco-
peptide-intermediate S. aureus  (GISA) (181,182 ). Intermediate resistance to
vancomycin is reported even more frequently among CNS (183,184 ).
Hemodialysis patients have played a prominent role in the epidemic of vancomycin
resistance. In 1988, a renal unit in London, England, reported one of the first cases of
VRE (185 ). In three studies, 12%–22% of hospitalized patients infected or colonized
with VRE were receiving hemodialysis (178,186,187 ). Furthermore, three of the first
five patients identified with VISA (or GISA) were on chronic hemodialysis, and one had
received acute dialysis (182 ).
Prevalence of VRE has increased rapidly at U.S. hospitals; among intensive care
unit patients with nosocomial infections reported to the National Nosocomial Infec-
tions Surveillance (NNIS) system, the percentage of enterococcal isolates resistant to
vancomycin increased from 0.5% in 1989 to 25.2% in 1999 (23 ) (CDC, unpublished
data, 2000). This increase is attributable to patient-to-patient transmission in health-
care settings and transmission of resistant genes among previously susceptible en-
terococci. Once vancomycin resistance has been transferred to a patient, antimicrobials
select for resistant organisms, causing them to increase in number relative to suscep-
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tible organisms. Prevalence of VRE colonization among patients varies in different
health-care settings; in hemodialysis centers, the reported prevalence in stool samples
ranged from 1% to 9% (188,189 ). In one center with a prevalence of 9%, three patients
developed VRE infections in 1 year (188 ).
Vancomycin Use
Dialysis patients have played a prominent role in the epidemic of vancomycin resis-
tance because this drug is used commonly in these patients, in part because vancomy-
cin can be conveniently administered to patients when they come in for hemodialysis
treatments. However, two studies indicate that cefazolin, a first-generation cepha-
losporin, could be substituted for vancomycin in many patients (190,191 ). One of these
studies reported that many pathogens causing infections in hemodialysis patients are
susceptible to cefazolin (190 ), and both studies reported therapeutic cefazolin blood
levels 48–72 hours after dosing, making in-center administration three times a week
after dialysis feasible.
Equipment, Supplies, and Environmental Surfaces
The hemodialysis machine and its components also can be vehicles for patient-to-
patient transmission of bloodborne viruses and pathogenic bacteria (24,192 ). The ex-
ternal surfaces of the machine are the most likely sources for contamination. These
include not only frequently touched surfaces (e.g., the control panel), but also attached
waste containers used during the priming of the dialyzers, blood tubing draped or
clipped to waste containers, and items placed on tops of machines for convenience
(e.g., dialyzer caps and medication vials).
Sterilization, Disinfection, and Cleaning
A sterilization procedure kills all microorganisms, including highly resistant bacte-
rial spores (24 ). Sterilization procedures are most commonly accomplished by steam
or ethylene oxide gas. For products that are heat sensitive, an FDA-cleared liquid chemi-
cal sterilant can be used with a long exposure time (i.e., 3–10 hours).
High-level disinfection kills all viruses and bacteria, but not high numbers of bacte-
rial spores. High-level disinfection can be accomplished by heat pasteurization or, more
commonly, by an FDA-cleared chemical sterilant, with an exposure time of 12–45 min-
utes. Sterilants and high-level disinfectants are designed to be used on medical de-
vices, not environmental surfaces. Intermediate-level disinfection kills bacteria and most
viruses and is accomplished by using a tuberculocidal “hospital disinfectant” (a term
used by the U.S. Environmental Protection Agency [EPA] in registering germicides) or
a 1:100 dilution of bleach (300–600 mg/L free chlorine). Low-level disinfection kills most
bacteria and is accomplished by using general purpose disinfectants. Intermediate and
low-level disinfectants are designed to be used on environmental surfaces; they also
can be used on noncritical medical devices, depending on the design and labeling
claim.
Cleaning eliminates dirt and some bacteria and viruses and is accomplished by
using a detergent or detergent germicide. Antiseptics (e.g., formulations with povi-
done-iodine, hexachlorophene, or chlorhexidene) are designed for use on skin and
tissue and should not be used on medical equipment or environmental surfaces.
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Regardless of the procedure used, cleaning with a germicidal detergent before dis-
infection (or sterilization) is essential to remove organic material (e.g., blood, mucous,
or feces), dirt, or debris. The presence of such material protects microorganisms from
the sterilization or disinfection process by physically blocking or inactivating the disin-
fectant or sterilant.
The choice of what procedure or which chemical germicide to use for medical de-
vices, instruments, and environmental surfaces depends on several factors, including
the need to maintain the structural integrity and function of the item and how the item
will be used. Three general categories of use for medical items are recognized, each of
which require different levels of sterilization or disinfection (193 ). These categories are
a) critical, which includes items introduced directly into the bloodstream or normally
sterile areas of the body (e.g., needles, catheters, hemodialyzers, blood tubing); b)
semicritical, which includes equipment that comes in contact with intact mucous mem-
branes (e.g., fiberoptic endoscopes, glass thermometers); and c) noncritical, which in-
cludes equipment that touches only intact skin (e.g., blood pressure cuffs). Semicritical
items are not generally used in dialysis units.
Internal Pathways of Hemodialysis Machines. In single-pass hemodialysis machines,
the internal fluid pathways are not subject to contamination with blood. If a dialyzer
leak occurs, dialysis fluid might become contaminated with blood, but this contami-
nated fluid is discarded through a drain and does not return to the dialysis machine to
contaminate predialyzer surfaces. For dialysis machines that use a dialysate recirculat-
ing system (e.g., some ultrafiltration control machines and those that regenerate the
dialysate), a blood leak in a dialyzer could contaminate the internal pathways of the
machine, which could in turn contaminate the dialysis fluid of subsequent patients
(192 ). However, procedures normally practiced after each use (i.e., draining the dialy-
sis fluid and rinsing and disinfecting the machine) will reduce the level of contamina-
tion to below infectious levels. In addition, an intact dialyzer membrane will not allow
passage of bacteria or viruses (24 ).
Pressure transducer filter protectors are used primarily to prevent contamination
and preserve the functioning of the pressure monitoring (i.e., arterial, venous, or both)
components of the hemodialysis machine. Hemodialysis machines usually have both
external (typically supplied with the blood tubing set) and internal protectors, with the
internal protector serving as a backup in case the external transducer protector fails.
Failure to use an external protector or to replace the protector when it becomes con-
taminated (i.e., wetted with saline or blood) can result in contamination of the internal
transducer protector, which in turn could allow transmission of bloodborne pathogens
(24 ). However, no epidemiologic evidence exists that contamination of the internal
transducer protector caused by failure of the external transducer protector has led to
either mixing of blood or the transmission of bloodborne agents.
Dialyzer Reprocessing. Approximately 80% of U.S. chronic hemodialysis centers
reprocess (i.e., reuse) dialyzers for the same patient (18 ), and guidelines for reprocess-
ing have been published elsewhere (see Suggested Readings). Although outbreaks of
bacterial infections and pyrogenic reactions have occurred because of inadequate re-
processing procedures and failure to maintain standards for water quality, reuse has
not been associated with transmission of bloodborne viruses. Any theoretical risk for
HBV transmission from reuse of dialyzers would primarily affect staff members who
handle these dialyzers. Although no increase in HBV (or HCV) infection among staff
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members who work in such centers has been reported, many centers do not reuse
dialyzers from HBsAg-positive patients (24 ).
Infection Control Precautions for Outpatient Hemodialysis
Settings Compared with Inpatient Hospital Settings
Contact transmission is the most important route by which pathogens are transmit-
ted in health-care settings, including hemodialysis units. Contact transmission occurs
most commonly when microorganisms from a patient are transferred to the hands of a
health-care worker who does not comply with infection control precautions, then
touches another patient. Less commonly, environmental surfaces (e.g., bed rails,
countertops) become contaminated and serve as an intermediate reservoir for patho-
gens; transmission can occur when a worker touches the surface then touches a patient
or when a patient touches the surface.
In the hemodialysis setting, contact transmission plays a major role in transmission
of bloodborne pathogens. If a health-care worker’s hands become contaminated with
virus-infected blood from one patient, the worker can transfer the virus to a second
patient’s skin or blood line access port, and the virus can be inoculated into that patient
when the skin or access port is punctured with a needle.
Contact transmission can be prevented by hand hygiene (i.e., hand washing or use
of a waterless hand rub), glove use, and disinfection of environmental surfaces. Of
these, hand hygiene is the most important. In addition, nonsterile disposable gloves
provide a protective barrier for workers’ hands, preventing them from becoming soiled
or contaminated, and reduce the likelihood that microorganisms present on the hands
of personnel will be transmitted to patients. However, even with glove use, hand wash-
ing is needed because pathogens deposited on the outer surface of gloves can be de-
tected on hands after glove removal, possibly because of holes or defects in the gloves,
leakage at the wrist, or contamination of hands during glove removal (194 ).
Standard Precautions are the system of infection control precautions recommended
for the inpatient hospital setting (195 ). Standard Precautions are used on all patients
and include use of gloves, gown, or mask whenever needed to prevent contact of the
health-care worker with blood, secretions, excretions, or contaminated items.
In addition to Standard Precautions, more stringent precautions are recommended
for hemodialysis units because of the increased potential for contamination with blood
and pathogenic microorganisms (see Infection Control Practices Recommended for
Hemodialysis Units). For example, infection control practices for hemodialysis units
restrict the use of common supplies, instruments, medications, and medication trays
and prohibit the use of a common medication cart.
For certain patients, including those infected or colonized with MRSA or VRE, con-
tact precautions are used in the inpatient hospital setting. Contact precautions include
a) placing the patient in a single room or with another patient infected or colonized with
the same organism; b) using gloves whenever entering the patient’s room; and c) using
a gown when entering the patient’s room if the potential exists for the worker’s cloth-
ing to have substantial contact with the patient, environmental surfaces, or items in the
patient’s room. Workers also should wear a gown if the patient has diarrhea, an ileo-
stomy, a colostomy, or wound drainage not contained by a dressing.
However, contact precautions are not recommended in hemodialysis units for pa-
tients infected or colonized with pathogenic bacteria for several reasons. First, although
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contact transmission of pathogenic bacteria is well-documented in hospitals, similar
transmission has not been well-documented in hemodialysis centers. Transmission
might not be apparent in dialysis centers, possibly because it occurs less frequently
than in acute-care hospitals or results in undetected colonization rather than overt in-
fection. Also, because dialysis patients are frequently hospitalized, determining whether
transmission occurred in the inpatient or outpatient setting is difficult. Second, con-
tamination of the patient’s skin, bedclothes, and environmental surfaces with patho-
genic bacteria is likely to be more common in hospital settings (where patients spend
24 hours a day) than in outpatient hemodialysis centers (where patients spend approxi-
mately 10 hours a week). Third, the routine use of infection control practices recom-
mended for hemodialysis units, which are more stringent than the Standard Precautions
routinely used in hospitals, should prevent transmission by the contact route.
RECOMMENDATIONS
Rationale
Preventing transmission among chronic hemodialysis patients of bloodborne vi-
ruses and pathogenic bacteria from both recognized and unrecognized sources of in-
fection requires implementation of a comprehensive infection control program. The
components of such a program include infection control practices specifically designed
for the hemodialysis setting, including routine serologic testing and immunization, sur-
veillance, and training and education (Box).
The infection control practices recommended for hemodialysis units will reduce
opportunities for patient-to-patient transmission of infectious agents, directly or indi-
rectly via contaminated devices, equipment and supplies, environmental surfaces, or
hands of personnel. These practices should be carried out routinely for all patients in
the chronic hemodialysis setting because of the increased potential for blood contami-
nation during hemodialysis and because many patients are colonized or infected with
pathogenic bacteria. Such practices include additional measures to prevent HBV trans-
mission because of the high titer of HBV and its ability to survive on environmental
surfaces. For patients at increased risk for transmission of pathogenic bacteria, includ-
BOX. Components of a comprehensive infection control program to prevent transmis-
sion of infections among chronic hemodialysis patients
• Infection control practices for hemodialysis units.
– Infection control precautions specifically designed to prevent transmission
of bloodborne viruses and pathogenic bacteria among patients.
– Routine serologic testing for hepatitis B virus and hepatitis C virus infections.
– Vaccination of susceptible patients against hepatitis B.
– Isolation of patients who test positive for hepatitis B surface antigen.
• Surveillance for infections and other adverse events.
• Infection control training and education.
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ing antimicrobial-resistant strains, additional precautions also might be necessary in
some circumstances. Furthermore, surveillance for infections and other adverse events
is required to monitor the effectiveness of infection control practices, as well as train-
ing and education of both staff members and patients to ensure that appropriate infec-
tion control behaviors and techniques are carried out.
Infection Control Practices for Hemodialysis Units
In each chronic hemodialysis unit, policies and practices should be reviewed and
updated to ensure that infection control practices recommended for hemodialysis units
are implemented and rigorously followed (see Recommended Infection Control Prac-
tices for Hemodialysis Units at a Glance). Intensive efforts must be made to educate
new staff members and reeducate existing staff members regarding these practices.
Infection Control Precautions for All Patients
During the process of hemodialysis, exposure to blood and potentially contami-
nated items can be routinely anticipated; thus, gloves are required whenever caring for
a patient or touching the patient’s equipment. To facilitate glove use, a supply of clean
nonsterile gloves and a glove discard container should be placed near each dialysis
station. Hands always should be washed after gloves are removed and between pa-
tient contacts, as well as after touching blood, body fluids, secretions, excretions, and
contaminated items. A sufficient number of sinks with warm water and soap should be
available to facilitate hand washing. If hands are not visibly soiled, use of a waterless
antiseptic hand rub can be substituted for hand washing.
Any item taken to a patient’s dialysis station could become contaminated with blood
and other body fluids and serve as a vehicle of transmission to other patients either
directly or by contamination of the hands of personnel. Therefore, items taken to a
patient’s dialysis station, including those placed on top of dialysis machines, should
either be disposed of, dedicated for use only on a single patient, or cleaned and disin-
fected before being returned to a common clean area or used for other patients. Un-
used medications or supplies (e.g., syringes, alcohol swabs) taken to the patient’s station
should not be returned to a common clean area or used on other patients.
Additional measures to prevent contamination of clean or sterile items include a)
preparing medications in a room or area separated from the patient treatment area
and designated only for medications; b) not handling or storing contaminated (i.e.,
used) supplies, equipment, blood samples, or biohazard containers in areas where
medications and clean (i.e., unused) equipment and supplies are handled; and c) deliv-
ering medications separately to each patient. Common carts should not be used within
the patient treatment area to prepare or distribute medications. If trays are used to
distribute medications, clean them before using for a different patient.
Intravenous medication vials labeled for single use, including erythropoetin, should
not be punctured more than once (196,197 ). Once a needle has entered a vial labeled
for single use, the sterility of the product can no longer be guaranteed. Residual medi-
cation from two or more vials should not be pooled into a single vial.
If a common supply cart is used to store clean supplies in the patient treatment
area, this cart should remain in a designated area at a sufficient distance from patient
stations to avoid contamination with blood. Such carts should not be moved between















Recommended Infection Control Practices for Hemodialysis Units at a Glance
Infection Control Precautions for All Patients
• Wear disposable gloves when caring for the patient or
touching the patient’s equipment at the dialysis station;
remove gloves and wash hands between each patient or
station.
• Items taken into the dialysis station should either be
disposed of, dedicated for use only on a single patient, or
cleaned and disinfected before being taken to a common
clean area or used on another patient.
– Nondisposable items that cannot be cleaned and
disinfected (e.g., adhesive tape, cloth-covered blood
pressure cuffs) should be dedicated for use only on a
single patient.
– Unused medications (including multiple dose vials
containing diluents) or supplies (e.g., syringes, alcohol
swabs) taken to the patient’s station should be used only
for that patient and should not be returned to a common
clean area or used on other patients.
• When multiple dose medication vials are used (including
vials containing diluents), prepare individual patient doses
in a clean (centralized) area away from dialysis stations and
deliver separately to each patient. Do not carry multiple
dose medication vials from station to station.
• Do not use common medication carts to deliver
medications to patients.  Do not carry medication vials,
syringes, alcohol swabs, or supplies in pockets. If trays are
used to deliver medications to individual patients, they
must be cleaned between patients.
Schedule for Routine Testing for Hepatitis B Virus (HBV)
and Hepatitis C Virus (HCV) Infections
















* Results of HBV testing should be known before the patient begins dialysis.
† HBsAg=hepatitis B surface antigen; Anti-HBc=antibody to hepatitis B core
antigen; Anti-HBs=antibody to hepatitis B surface antigen; Anti-HCV=antibody
to hepatitis C virus; ALT=alanine aminotransferase.


















• Vaccinate all susceptible patients against hepatitis B.
• Test for anti-HBs 1-2 months after last dose.
– If anti-HBs is <10 mIU/mL, consider patient
susceptible, revaccinate with an additional three
doses, and retest for anti-HBs.
– If anti-HBs is >10 mIU/mL, consider patient immune,
and retest annually.
– Give booster dose of vaccine if anti-HBs declines to
<10 mIU/mL and continue to retest annually.
Management of HBsAg-Positive Patients
• Follow infection control practices for hemodialysis units
for all patients.
• Dialyze HBsAg-positive patients in a separate room
using separate machines, equipment, instruments, and
supplies.
• Staff members caring for HBsAg-positive patients
should not care for HBV-susceptible patients at the
same time (e.g., during the same shift or during patient
changeover).
• Clean areas should be clearly designated for the
preparation, handling, and storage of medications and
unused supplies and equipment. Clean areas should be
clearly separated from contaminated areas where used
supplies and equipment are handled. Do not handle and
store medications or clean supplies in the same or an
adjacent area to where used equipment or blood samples
are handled.
• Use external venous and arterial pressure transducer
filters/protectors for each patient treatment to prevent
blood contamination of the dialysis machines’ pressure
monitors. Change filters/protectors between each patient
treatment, and do not reuse them. Internal transducer
filters do not need to be changed routinely between
patients.
• Clean and disinfect the dialysis station (e.g., chairs, beds,
tables, machines) between patients.
– Give special attention to cleaning control panels on the
dialysis machines and other surfaces that are frequently
touched and potentially contaminated with patients’
blood.
– Discard all fluid and clean and disinfect all surfaces and
containers associated with the prime waste (including
buckets attached to the machines).
• For dialyzers and blood tubing that will be reprocessed,
cap dialyzer ports and clamp tubing. Place all used
dialyzers and tubing in leakproof containers for transport
from station to reprocessing or disposal area.
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Staff members should wear gowns, face shields, eye wear, or masks to protect them-
selves and prevent soiling of clothing when performing procedures during which spurt-
ing or spattering of blood might occur (e.g., during initiation and termination of dialysis,
cleaning of dialyzers, and centrifugation of blood). Such protective clothing or gear
should be changed if it becomes soiled with blood, body fluids, secretions, or excre-
tions. Staff members should not eat, drink, or smoke in the dialysis treatment area or in
the laboratory. However, patients can be served meals or eat food brought from home
at their dialysis station. The glasses, dishes, and other utensils should be cleaned in the
usual manner; no special care of these items is needed.
Cleaning and Disinfection. Establish written protocols for cleaning and disinfecting
surfaces and equipment in the dialysis unit, including careful mechanical cleaning be-
fore any disinfection process (Table 2). If the manufacturer has provided instructions on
sterilization or disinfection of the item, these instructions should be followed. For each
chemical sterilant and disinfectant, follow the manufacturer’s instructions regarding
use, including appropriate dilution and contact time.
After each patient treatment, clean environmental surfaces at the dialysis station,
including the dialysis bed or chair, countertops, and external surfaces of the dialysis
machine, including containers associated with the prime waste. Use any soap, deter-
gent, or detergent germicide. Between uses of medical equipment (e.g., scissors, he-
mostats, clamps, stethoscopes, blood pressure cuffs), clean and apply a hospital
disinfectant (i.e., low-level disinfection); if the item is visibly contaminated with blood,
use a tuberculocidal disinfectant (i.e., intermediate-level disinfection).
For a blood spill, immediately clean the area with a cloth soaked with a tubercu-
locidal disinfectant or a 1:100 dilution of household bleach (300–600 mg/L free chlorine)
(i.e., intermediate-level disinfection). The staff member doing the cleaning should wear
gloves, and the cloth should be placed in a bucket or other leakproof container. After all
visible blood is cleaned, use a new cloth or towel to apply disinfectant a second time.
Published methods should be used to clean and disinfect the water treatment and
distribution system and the internal circuits of the dialysis machine, as well as to repro-
TABLE 2. Disinfection procedures recommended for commonly used items or surfaces
in hemodialysis units
Low-Level Intermediate-Level
Item or Surface Disinfection* Disinfection*
Gross blood spills or items contaminated
with visible blood X
Hemodialyzer port caps X
Interior pathways of dialysis machine X
Water treatment and distribution system X X†
Scissors, hemostats, clamps, blood
pressure cuffs, stethoscopes X X§
Environmental surfaces, including exterior
surfaces of hemodialysis machines X
* Careful mechanical cleaning to remove debris should always be done before disinfection.
† Water treatment and distribution systems of dialysis fluid concentrates require more extensive
disinfection if significant biofilm is present within the system.
§ If item is visibly contaminated with blood, use a tuberculocidal disinfectant.
Vol. 50 / No. RR-5 MMWR 23
cess dialyzers for reuse (see Suggested Readings). These methods are designed to
control bacterial contamination, but will also eliminate bloodborne viruses. For single-
pass machines, perform rinsing and disinfection procedures at the beginning or end of
the day. For batch recirculating machines, drain, rinse, and disinfect after each use.
Follow the same methods for cleaning and disinfection if a blood leak has occurred,
regardless of the type of dialysis machine used. Routine bacteriologic assays of water
and dialysis fluids should be performed according to the recommendations of the As-
sociation for the Advancement of Medical Instrumentation (see Suggested Readings).
Venous pressure transducer protectors should be used to cover pressure monitors
and should be changed between patients, not reused. If the external transducer protec-
tor becomes wet, replace immediately and inspect the protector. If fluid is visible on the
side of the transducer protector that faces the machine, have qualified personnel open
the machine after the treatment is completed and check for contamination. This in-
cludes inspection for possible blood contamination of the internal pressure tubing set
and pressure sensing port. If contamination has occurred, the machine must be taken
out of service and disinfected using either 1:100 dilution of bleach (300–600 mg/L free
chlorine) or a commercially available, EPA-registered tuberculocidal germicide before
reuse. Frequent blood line pressure alarms or frequent adjusting of blood drip cham-
ber levels can be an indicator of this problem. Taken separately, these incidents could
be characterized as isolated malfunctions. However, the potential public health signifi-
cance of the total number of incidents nationwide make it imperative that all incidents
of equipment contamination be reported immediately to the FDA (800-FDA-1088).
Housekeeping staff members in the dialysis facility should promptly remove soil
and potentially infectious waste and maintain an environment that enhances patient
care. All disposable items should be placed in bags thick enough to prevent leakage.
Wastes generated by the hemodialysis facility might be contaminated with blood and
should be considered infectious and handled accordingly. These solid medical wastes
should be disposed of properly in an incinerator or sanitary landfill, according to local
and state regulations governing medical waste disposal.
Hemodialysis in Acute-Care Settings. For patients with acute renal failure who re-
ceive hemodialysis in acute-care settings, Standard Precautions as applied in all health-
care settings are sufficient to prevent transmission of bloodborne viruses. However,
when chronic hemodialysis patients receive maintenance hemodialysis while hospital-
ized, infection control precautions specifically designed for chronic hemodialysis units
(see Recommended Practices at a Glance) should be applied to these patients. If both
acute and chronic renal failure patients receive hemodialysis in the same unit, these
infection control precautions should be applied to all patients.
Regardless of where in the acute-care setting chronic hemodialysis patients receive
dialysis, the HBsAg status of all such patients should be ascertained at the time of
admission to the hospital, by either a written report from the referring center (including
the most recent date testing was performed) or by a serologic test. The HBV serologic
status should be prominently placed in patients’ hospital records, and all health-care
personnel assigned to these patients, as well as the infection control practitioner, should
be aware of the patients’ serologic status. While hospitalized, HBsAg-positive chronic
hemodialysis patients should undergo dialysis in a separate room and use separate
machines, equipment, instruments, supplies, and medications designated only for
HBsAg-positive patients (see Prevention and Management of HBV Infection). While
HBsAg-positive patients are receiving dialysis, staff members who are caring for them
should not care for susceptible patients.
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Routine Serologic Testing
Chronic Hemodialysis Patients. Routinely test all chronic hemodialysis patients for
HBV and HCV infection (see Recommended Practices at a Glance), promptly review
results, and ensure that patients are managed appropriately based on their testing re-
sults (see later recommendations for each virus). Communicate test results (positive
and negative) to other units or hospitals when patients are transferred for care. Routine
testing for HDV or HIV infection for purposes of infection control is not recommended.
The HBV serologic status (i.e., HBsAg, total anti-HBc, and anti-HBs) of all patients
should be known before admission to the hemodialysis unit. For patients transferred
from another unit, test results should be obtained before the patients’ transfer. If a
patient’s HBV serologic status is not known at the time of admission, testing should be
completed within 7 days. The hemodialysis unit should ensure that the laboratory per-
forming the testing for anti-HBs can define a 10 mIU/mL concentration to determine
protective levels of antibody.
Routine HCV testing should include use of both an EIA to test for anti-HCV and
supplemental or confirmatory testing with an additional, more specific assay (Figure).
Use of RT-PCR for HCV RNA as the primary test for routine screening is not recom-
mended because few HCV infections will be identified in anti-HCV negative patients.
Source: CDC. Recommendations for prevention and control of hepatitis C virus (HCV) infection
and HCV-related chronic disease. MMWR 1998;47(No. RR-19):27.
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However, if ALT levels are persistently abnormal in patients who are anti-HCV negative
in the absence of another etiology, testing for HCV RNA should be considered (for
proper specimen collection and handling, see Hepatitis C Virus Infection, Screening
and Diagnostic Tests).
Hemodialysis Staff Members. Previously, testing for HBV infection was recom-
mended for all staff members at the time of employment and for susceptible staff
members at routine intervals thereafter (198 ); however, such testing is no longer con-
sidered necessary. The risk for HBV infection among hemodialysis staff members is no
greater than that for other health-care workers. Thus, routine testing of staff members
is not recommended except when required to document response to hepatitis B vacci-
nation (see Postvaccination Testing and Revaccination of Nonresponders). Routine test-
ing of staff members for HCV, HDV, or HIV infection is not recommended.
Hepatitis B Vaccination
Vaccine Schedule and Dose. Hepatitis B vaccination is recommended for all suscep-
tible chronic hemodialysis patients and for all staff members (Table 3). Vaccination is
recommended for pre–end-stage renal disease patients before they become dialysis
dependent and for peritoneal and home dialysis patients because they might require
in-center hemodialysis. Hepatitis B vaccine should be administered by the intramuscu-
lar route and only in the deltoid muscle for adults and children. Intradermal or subcuta-
neous administration of hepatitis B vaccine is not recommended.
If an adult patient begins the vaccine series with a standard dose before beginning
hemodialysis treatment, then moves to hemodialysis treatment before completing the
series, complete the series using the higher dose recommended for hemodialysis pa-
tients (Table 3). No specific recommendations have been made for higher doses for
pediatric hemodialysis patients. If a lower than recommended vaccine dose is adminis-
tered to either adults or children, the dose should be repeated.
TABLE 3. Doses and schedules of licensed hepatitis B vaccines for hemodialysis patients
and staff members
Recombivax HB™* Engerix-B®†
Group Dose Volume Schedule Dose Volume Schedule
Patients aged >20 years
     Predialysis§ 10 µg 1.0 mL 0, 1, and 20 µg 1.0 mL 0, 1, and
6 months  6 months
     Dialysis-dependent 40 µg 1.0 mL¶ 0, 1, and 40 µg 2–1.0 mL 0, 1, 2, and
 6 months doses at  6 months
one site
Patients aged <20 years** 5 µg 0.5 mL 0, 1, and 10 µg 0.5 mL 0, 1, and
6 months 6 months
Staff members 10 µg 1.0 mL 0, 1, and 20 µg 1.0 mL 0, 1, and
aged >20 years 6 months 6 months
* Merck & Company, Inc., West Point, Pennsylvania.
† SmithKline Beecham Biologicals, Philadelphia, Pennsylvania.
§ Immunogenicity might depend on degree of renal insufficiency.
¶ Special formulation.
** Doses for all persons aged <20 years approved by the U.S. Food and Drug Administration; for hemodialysis
patients, higher doses might be more immunogenic.
Note: All doses should be administered in the deltoid by the intramuscular route.
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If the vaccination series is interrupted after the first dose, the second dose should be
administered as soon as possible. For the three-dose primary vaccine series, the sec-
ond and third doses should be separated by an interval of at least 2 months; if only the
third dose is delayed, that dose should be administered when convenient. When hepa-
titis B vaccine has been administered at the same time as other vaccines, no interfer-
ence with the antibody response of the other vaccines has been demonstrated.
Postvaccination Testing and Revaccination of Nonresponders. Test all vaccinees for
anti-HBs 1–2 months after the last primary vaccine dose, to determine their response to
the vaccine (adequate response is defined as >10 mIU/mL). Patients and staff members
who do not respond to the primary vaccine series should be revaccinated with three
additional doses and retested for response. No additional doses of vaccine are war-
ranted for those who do not respond to the second series.
Evaluate staff members who do not respond to revaccination to determine if they
are HBsAg positive (199 ). Persons who are HBsAg positive should be counseled ac-
cordingly (e.g., need for medical evaluation, vaccination of sexual and household con-
tacts). Primary nonresponders to vaccination who are HBsAg negative should be
considered susceptible to HBV infection and counseled regarding precautions to pre-
vent HBV infection and the need to obtain postexposure prophylaxis with hepatitis B
immune globulin for any known or probable percutaneous or mucosal exposure to
HBsAg-positive blood (199 ).
Follow-Up of Vaccine Responders. Retest patients who respond to the vaccine an-
nually for anti-HBs. If anti-HBs declines to <10 mIU/mL, administer a booster dose of
hepatitis B vaccine and continue to retest annually. Retesting immediately after the
booster dose is not necessary. For staff members who respond to the vaccine, booster
doses of vaccine are not necessary, and periodic serologic testing to monitor antibody
concentrations is not recommended (199 ).
Patients with a History of Vaccination. Routine childhood vaccination against hepa-
titis B has been recommended since 1991 and routine adolescent vaccination since
1995 (89,198 ). Thus, many persons who develop end-stage renal failure will have a
history of vaccination against hepatitis B. These persons should have responded to the
vaccine when their immune status was normal, but if their anti-HBs levels are
<10 mIU/mL when they begin dialysis, they should be revaccinated with a complete
primary series.
Prevention and Management of HBV Infection
Preventing HBV transmission among chronic hemodialysis patients requires a) in-
fection control precautions recommended for all hemodialysis patients; b) routine se-
rologic testing for markers of HBV infection and prompt review of results; c) isolation of
HBsAg-positive patients with dedicated room, machine, other equipment, supplies, and
staff members; and d) vaccination. Additional infection control practices are needed
because of the potential for environmentally mediated transmission of HBV, rather than
internal contamination of dialysis machines. The need for routine follow-up testing,
vaccination, or isolation is based on patients’ serologic status (Table 1 and Recom-
mended Practices at a Glance).
HBV-Susceptible Patients. Vaccinate all susceptible patients (see Hepatitis B Vacci-
nation). Test susceptible patients monthly for HBsAg, including those who a) have not
yet received hepatitis B vaccine, b) are in the process of being vaccinated, or c) have not
adequately responded to vaccination. Although the incidence of HBV infection is low
Vol. 50 / No. RR-5 MMWR 27
among chronic hemodialysis patients, preventing transmission depends on timely de-
tection of patients converting from HBsAg negative to HBsAg positive and rapid imple-
mentation of isolation procedures before cross-contamination can occur.
HBsAg Seroconversions. Report HBsAg-positive seroconversions to the local health
department as required by law or regulation. When a seroconversion occurs, review all
patients’ routine laboratory test results to identify additional cases. Perform additional
testing as indicated later in this section. Investigate potential sources for infection to
determine if transmission might have occurred within the dialysis unit, including re-
view of newly infected patients’ recent medical history (e.g., blood transfusion, hospi-
talization), history of high-risk behavior (e.g., injecting-drug use, sexual activity), and
unit practices and procedures.
In patients newly infected with HBV, HBsAg often is the only serologic marker ini-
tially detected; repeat HBsAg testing and test for anti-HBc (including IgM anti-HBc) 1–2
months later. Six months later, repeat HBsAg testing and test for anti-HBs to determine
clinical outcome and need for counseling, medical evaluation, and vaccination of con-
tacts. Patients who become HBsAg negative are no longer infectious and can be re-
moved from isolation.
HBV-Infected Patients. To isolate HBsAg-positive patients, designate a separate
room for their treatment and dedicate machines, equipment, instruments, supplies,
and medications that will not be used by HBV-susceptible patients. Most importantly,
staff members who are caring for HBsAg-positive patients should not care for suscep-
tible patients at the same time, including during the period when dialysis is terminated
on one patient and initiated on another.
Newly opened units should have isolation rooms for the dialysis of HBsAg-positive
patients. For existing units in which a separate room is not possible, HBsAg-positive
patients should be separated from HBV-susceptible patients in an area removed from
the mainstream of activity and should undergo dialysis on dedicated machines. If a
machine that has been used on an HBsAg-positive patient is needed for an HBV-
susceptible patient, internal pathways of the machine can be disinfected using conven-
tional protocols and external surfaces cleaned using soap and water or a detergent
germicide.
Dialyzers should not be reused on HBsAg-positive patients. Because HBV is effi-
ciently transmitted through occupational exposure to blood, reprocessing dialyzers
from HBsAg-positive patients might place HBV-susceptible staff members at increased
risk for infection.
Chronically infected patients (i.e., those who are HBsAg positive, total anti-HBc posi-
tive, and IgM anti-HBc negative) are infectious to others and are at risk for chronic liver
disease. They should be counseled regarding preventing transmission to others, their
household and sexual partners should receive hepatitis B vaccine, and they should be
evaluated (by consultation or referral, if appropriate) for the presence or development
of chronic liver disease according to current medical practice guidelines. Persons with
chronic liver disease should be vaccinated against hepatitis A, if susceptible.
Chronically infected patients do not require any routine follow-up testing for pur-
poses of infection control. However, annual testing for HBsAg is reasonable to detect
the small percentage of HBV-infected patients who might lose their HBsAg.
HBV-Immune Patients. Annual anti-HBs testing of patients who are positive for anti-
HBs (>10 mIU/mL) and negative for anti-HBc determines the need for booster doses of
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vaccine to ensure that protective levels of antibody are maintained. No routine follow-
up testing is necessary for patients who are positive for both anti-HBs and anti-HBc.
HBV-immune patients can undergo dialysis in the same area as HBsAg-positive pa-
tients, or they can serve as a geographic buffer between HBsAg-positive and HBV-
susceptible patients. Staff members can be assigned to care for both infected and
immune patients on the same shift.
Isolated Anti-HBc–Positive Patients. Patients who test positive for isolated anti-HBc
(i.e., those who are anti-HBc positive, HBsAg negative, and anti-HBs negative) should
be retested on a separate serum sample for total anti-HBc, and if positive, for IgM anti-
HBc. The following guidelines should be used for interpretation and follow-up:
• If total anti-HBc is negative, consider patient susceptible, and follow
recommendations for vaccination.
• If total anti-HBc is positive and IgM anti-HBc is negative, follow recommendations
for vaccination.
– If anti-HBs is <10 mIU/mL even after revaccination, test for HBV DNA.
– If HBV DNA is negative, consider patient susceptible (i.e., the anti-HBc result is
a false positive), and test monthly for HBsAg.
– If HBV DNA is positive, consider patient as having past infection or “low-level”
chronic infection (i.e., the anti-HBc result is a true positive); no further testing is
necessary.
– Isolation is not necessary because HBsAg is not detectable.
• If both total and IgM anti-HBc are positive, consider patient recently infected and
test for anti-HBs in 4–6 months; no further routine testing is necessary.
– Isolation is not necessary because HBsAg is not detectable.
Prevention and Management of HCV Infection
HCV transmission within the dialysis environment can be prevented by strict adher-
ence to infection control precautions recommended for all hemodialysis patients (see
Recommended Practices at a Glance). Although isolation of HCV-infected patients is
not recommended, routine testing for ALT and anti-HCV is important for monitoring
transmission within centers and ensuring that appropriate precautions are being prop-
erly and consistently used.
HCV-Negative Patients. Monthly ALT testing will facilitate timely detection of new
infections and provide a pattern from which to determine when exposure or infection
might have occurred. In the absence of unexplained ALT elevations, testing for anti-
HCV every 6 months should be sufficient to monitor the occurrence of new HCV infec-
tions. If unexplained ALT elevations are observed in patients who are anti-HCV negative,
repeat anti-HCV testing is warranted. If unexplained ALT elevations persist in patients
who repeatedly test anti-HCV negative, testing for HCV RNA should be considered.
Anti-HCV Seroconversions. Report anti-HCV–positive seroconversions to the local
health department as required by law or regulation. When a seroconversion occurs,
review all other patients’ routine laboratory test results to identify additional cases.
Perform additional testing as indicated later in this section. Investigate potential sources
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for infection to determine if transmission might have occurred within the dialysis unit,
including review of newly infected patients’ recent medical history (e.g., blood transfu-
sion, hospitalization), history of high-risk behavior (e.g., injecting-drug use, sexual ac-
tivity), and unit practices and procedures.
If >1 patient seroconverts from anti-HCV negative to positive during a 6-month pe-
riod, more frequent (e.g., every 1–3 months) anti-HCV testing of HCV-negative patients
could be warranted for a limited time (e.g., 3–6 months) to detect additional infections.
If no additional newly infected patients are identified, resume semiannual testing. If
ongoing HCV transmission among patients is identified, implement control measures
based on results of investigation of potential sources for transmission and monitor
their effectiveness (e.g., perform more frequent anti-HCV testing of HCV-negative pa-
tients for 6–12 months before resuming semiannual testing).
HCV-Positive Patients. Patients who are anti-HCV positive (or HCV RNA positive) do
not have to be isolated from other patients or dialyzed separately on dedicated ma-
chines. Furthermore, they can participate in dialyzer reuse programs. Unlike HBV, HCV
is not transmitted efficiently through occupational exposures. Thus, reprocessing dia-
lyzers from HCV-positive patients should not place staff members at increased risk for
infection.
HCV-positive persons should be evaluated (by consultation or referral, if appropri-
ate) for the presence or development of chronic liver disease according to current medi-
cal practice guidelines. They also should receive information concerning how they can
prevent further harm to their liver and prevent transmitting HCV to others (116,141 ).
Persons with chronic liver disease should be vaccinated against hepatitis A, if suscep-
tible.
Prevention and Management of HDV Infection
Because of the low prevalence of HDV infection in the United States, routine testing
of hemodialysis patients is not necessary or recommended. However, if a patient is
known to be infected with HDV, or if evidence exists of transmission of HDV in a dialysis
center, screening for delta antibody is warranted. Because HDV depends on an HBV-
infected host for replication, prevention of HBV infection will prevent HDV infection in a
person susceptible to HBV. Patients who are known to be infected with HDV should be
isolated from all other dialysis patients, especially those who are HBsAg-positive.
Prevention and Management of HIV Infection
Routine testing of hemodialysis patients for HIV infection for infection control pur-
poses is not necessary or recommended. However, patients with risk factors for HIV
infection should be tested so that, if infected, they can receive proper medical care and
counseling regarding preventing transmission of the virus (201 ).
Infection control precautions recommended for all hemodialysis patients (see Rec-
ommended Practices at a Glance) are sufficient to prevent HIV transmission between
patients. HIV-infected patients do not have to be isolated from other patients or dia-
lyzed separately on dedicated machines. In addition, they can participate in dialyzer
reuse programs. Because HIV is not transmitted efficiently through occupational expo-
sures, reprocessing dialyzers from HIV-positive patients should not place staff mem-
bers at increased risk for infection.
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Prevention and Management of Bacterial Infections
Follow published guidelines for judicious use of antimicrobials, particularly vanco-
mycin, to reduce selection for antimicrobial-resistant pathogens (202 ). Infection con-
trol precautions recommended for all hemodialysis patients (see Recommended
Practices at a Glance) are adequate to prevent transmission for most patients infected
or colonized with pathogenic bacteria, including antimicrobial-resistant strains. How-
ever, additional infection control precautions should be considered for treatment of
patients who might be at increased risk for transmitting pathogenic bacteria. Such pa-
tients include those with either a) an infected skin wound with drainage that is not
contained by dressings (the drainage does not have to be culture positive for VRE,
MRSA, or any specific pathogen) or b) fecal incontinence or diarrhea uncontrolled with
personal hygiene measures. For these patients, consider using the following additional
precautions: a) staff members treating the patient should wear a separate gown over
their usual clothing and remove the gown when finished caring for the patient and b)
dialyze the patient at a station with as few adjacent stations as possible (e.g., at the end
or corner of the unit).
SURVEILLANCE FOR INFECTIONS AND OTHER
ADVERSE EVENTS
Develop and maintain a separate centralized record-keeping system (e.g., log book
or electronic file) to record the results of patients’ vaccination status, serologic testing
results for viral hepatitis (including ALT), episodes of bacteremia or loss of the vascular
access caused by infection (including date of onset, site of infection, genus and species
of the infecting organism, and selected antimicrobial susceptibility results),* and ad-
verse events (e.g., blood leaks and spills, dialysis machine malfunctions). Designate a
staff person to promptly review the results of routine testing each time such testing is
performed and periodically review recorded episodes of bacteremia or vascular access
infections. Specify a procedure for actions required when changes occur in test results
or in the frequency of episodes of bacteremias or vascular access loss because of infec-
tion. Maintain records for each patient that include the location of the dialysis station
and machine number used for each dialysis session and the names of staff members
who connect and disconnect the patient to and from a machine.
INFECTION CONTROL TRAINING AND EDUCATION
Training and education is recommended for both staff members and patients (or
their family care givers). Training should be appropriate to the cognitive level of the
staff member, patient, or family member, and rationales should be provided for appro-
priate infection control behaviors and techniques to increase compliance. Regulations
and recommendations regarding infection control training for health-care workers in
general, and dialysis personnel in particular, have been previously published
*Hemodialysis units interested in participating in a formal surveillance system for bacterial
infections should consult CDC’s Surveillance for Bloodstream and Vascular Access Infections in
Outpatient Hemodialysis Centers. More information is available on the Internet at <http://
www.cdc.gov/ncidod/hip/Dialysis/DSN_manual.PDF>.
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(180,203–205 ). The following recommendations are intended to highlight and aug-
ment the earlier recommendations.
• Training and education for all employees at risk for occupational exposure to
blood should be provided at least annually, given to new employees before they
begin working in the unit, and documented. At a minimum, they should include
information on the following topics:
– proper hand hygiene technique;
– proper use of protective equipment;
– modes of transmission for bloodborne viruses, pathogenic bacteria, and other
microorganisms as appropriate;
– infection control practices recommended for hemodialysis units and how they
differ from Standard Precautions recommended for other health-care settings;
– proper handling and delivery of patient medications;
– rationale for segregating HBsAg-positive patients with a separate room,
machine, instruments, supplies, medications, and staff members;
– proper infection control techniques for initiation, care, and maintenance of
access sites;
– housekeeping to minimize transmission of microorganisms, including proper
methods to clean and disinfect equipment and environmental surfaces; and
– centralized record keeping to monitor and prevent complications, including
routine serologic testing results for HBV and HCV, hepatitis B vaccine status,
episodes of bacteremia and loss of access caused by infection, and other
adverse events. Records of surveillance for water and dialysate quality should
also be maintained.
• Training and education of patients (or family members for patients unable to be
responsible for their own care) regarding infection control practices should be
given on admission to dialysis and at least annually thereafter and should address
the following topics:
– personal hygiene and hand washing technique;
– patient responsibility for proper care of the access and recognition of signs of
infection, which should be reviewed each time the patient has a change in
access type; and
– recommended vaccinations (206 ).
FUTURE DIRECTIONS
Infection control strategies that prevent and control HBV infection among hemodi-
alysis patients are well-established. Areas that need additional research include deter-
mining the ideal hepatitis B vaccine dosage regimen for pre- and postdialysis pediatric
patients and for predialysis adult patients, as well as the optimal timing for follow-up
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testing and administration of booster doses among vaccine responders. In addition,
further studies are needed to clarify the specific factors responsible for transmission of
HCV among hemodialysis patients and to evaluate the effect of the current recommen-
dations on prevention and control of HCV infection in this setting.
Many areas related to bacterial infections in chronic hemodialysis patients need
additional information. Studies are needed on the prevalence and epidemiology of
bacterial infections among chronic hemodialysis patients and the patient care practices
(e.g., those related to vascular access care and puncture) that would be most useful in
preventing bacterial infections. Because of the prominent role of dialysis patients in the
epidemic of antimicrobial resistance, researchers need to learn more regarding opti-
mal strategies to ensure judicious use of antimicrobials in these patients. Additional
topics for future research include determining the frequency of transmission of patho-
genic bacteria in the dialysis unit and whether additional precautions are necessary to
prevent such transmission.
This document is available on the Internet at <http://www.cdc.gov/hepatitis>. Cop-
ies also can be obtained by using the order form at this Internet site or by writing the
Hepatitis Branch, Mailstop G37, CDC, Atlanta, GA 30333.
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GOAL AND OBJECTIVES
This MMWR provides recommendations regarding the prevention of bloodborne virus and bacterial infections in
hemodialysis settings. These recommendations were prepared by CDC staff members after consultation with staff
members from other federal agencies and specialists in the field. The goal of this report is to serve as a resource
for health-care professionals, public health officials, and organizations involved in the care of patients receiving
hemodialysis. Upon completion of this continuing education activity, the reader should be able to describe the
recommendations for a) preventing bloodborne virus infections in hemodialysis settings, b) preventing bacterial
infections in hemodialysis settings, c) developing and maintaining surveillance systems for infections and other
adverse events, and d) developing training and education programs.
To receive continuing education credit, please answer all of the following questions.
1. A comprehensive infection control program in a dialysis setting should include which of the following
components? (Indicate all that apply.)
A. Routine serologic testing for hepatitis B virus (HBV) and hepatitis C virus (HCV) infection.
B. Vaccination of susceptible patients against hepatitis B.
C. Surveillance for infections and other adverse events.
D. Infection control training and education.
E. Isolation of patients who test positive for hepatitis B surface antigen (HBsAg).
2. Which of the following statements regarding hepatitis B vaccination in the dialysis setting are true?
(Indicate all that apply.)
A. Hepatitis B vaccine is recommended for all susceptible chronic hemodialysis patients.
B. Hepatitis B vaccine is recommended for all susceptible staff members.
C. All vaccinees should be tested 1–2 months after completion of the series to determine their response to
the vaccine.
D. Nonresponders should be given an additional three doses of vaccine and retested.
3. How should chronic dialysis patients who respond to hepatitis B vaccine be followed?
A. No follow-up is necessary.
B. Give a booster dose of vaccine annually.
C. Test for antibody to HBsAg (anti-HBs) annually and give a booster dose of vaccine if anti-HBs is <10 milli-
International Units (mIU)/mL.
D. Test for anti-HBs annually, give a booster dose of vaccine if anti-HBs is <10 mIU/ml, and retest for anti-
HBs 1–2 months after booster.
4. Which of the following statements regarding the management of HBsAg-positive patients are true?
(Indicate all that apply.)
A. HBsAg-positive patients do not have to be isolated from HBV-susceptible patients.
B. HBV-immune patients can act as a geographic buffer between HBsAg-positive and HBV-susceptible
patients.
C. Dedicated equipment should be used for HBsAg-positive patients.
D. Staff members who are caring for HBsAg-positive patients can also care for HBV-susceptible patients at
the same time.
E. Dialyzers should not be reused on HBsAg-positive patients.
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5. Which of the following statements regarding the management of HCV-positive patients are true?
A. HCV-positive patients do not have to be isolated from HCV-susceptible patients.
B. Staff members who are caring for HCV-positive patients can also care for HCV-negative patients at the
same time.
C. Dialyzers can be reused on HCV-positive patients.
D. All of the above.
E. None of the above.
6. From an infection control standpoint, what is the best way to deliver medications to dialysis patients?
A. Deliver medications separately to each patient.
B. Use a medication cart to deliver medications to each patient.
C. Prepare all medications at each patient’s dialysis station and return unused supplies to a common area
so they can be used for other patients.
D. None of the above.
7. How should dialysis patients infected or colonized with methicillin-resistant Staphylococcus aureus and
vancomycin-resistant enterococci be treated in the dialysis unit?
A. No additional precautions are necessary.
B. Contact precautions should always be followed.
C. Dedicated equipment should be used.
D. If a patient has an infected skin wound with drainage that is not contained by dressings, fecal
incontinence, or diarrhea uncontrolled with personal hygiene measures, staff members treating the
patient should wear a separate gown and dialyze the patient as far away from other patients as possible.
8. Which of the following statements are true regarding instruments and supplies that are taken to the
patient’s dialysis station but not used?
A. They can be returned to the clean supply area for use on other patients.
B. They must be disposed of or cleaned and disinfected before use on another patient.
C. They can be used for another patient if not visibly soiled.
D. They can be kept at that dialysis station for use on the next patient.
9. Which of the following statements are true regarding hand washing?
A. Use of a waterless antiseptic hand rub can always be substituted for hand washing.
B. Use of a waterless antiseptic hand rub can never be substituted for hand washing.
C. Use of a waterless antiseptic hand rub can be substituted for hand washing only if no drug-resistant
pathogens are present in the unit.
D. Use of a waterless antiseptic hand rub can be substituted for hand washing if hands are not visibly
soiled.
10. Indicate your work setting.
A. State/local health department.
B. Other public health setting.
C. Hospital clinic/private practice.
D. Managed care organization.
E. Academic institution.
F. Other.
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11. Which best describes your professional activities?






12. I plan to use these recommendations as the basis for . . . (Indicate all that apply.)
A. health education materials.
B.  insurance reimbursement policies.
C. local practice guidelines.
D. public policy.
E. other.







14. How much time did you spend reading this report and completing the exam?
A. 1–1.5 hours.
B. More than 1.5 hours but fewer than 2 hours.
C. 2–2.5 hours.
D. More than 2.5 hours.
15. After reading this report, I am confident I can describe the recommendations for preventing bloodborne
virus infections in hemodialysis settings.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
16. After reading this report, I am confident I can describe the recommendations for preventing bacterial
infections in hemodialysis settings.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
Vol. 50 / No. RR-5 MMWR CE–5
17. After reading this report, I am confident I can describe the recommendations for developing and
maintaining surveillance systems for infections and other adverse events.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.




C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
19. The objectives are relevant to the goals of this report.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
20. The tables and figure are useful.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
21. Overall, the presentation of the report enhanced my ability to understand the material.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
22. These recommendations will affect my practice.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
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Correct answers for questions 1–9.
1. A, B, C, D, E; 2. A, B, C, D; 3. C; 4. B, C, E; 5. D; 6. A; 7. D; 8. B; 9. D.
23. How did you learn about this continuing education activity?
A. Internet.
B. Advertisement (e.g., fact sheet, MMWR cover, newsletter, or journal).
C. Coworker/supervisor.
D. Conference presentation.
E. MMWR  subscription.
F. Other.
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MMWR Response Form for Continuing Education Credit
April 27, 2001/Vol. 50/No. RR-5
Recommendations for Preventing Transmission of Infections
Among Chronic Hemodialysis Patients
Check One
Last Name First Name CME Credit
CEU Credit
Street/Address or P.O. Box CNE Credit
Apartment or Suite
City State Zip Code
Fill in the appropriate blocks to indicate your answers. Remember, you must answer all of the questions to receive
continuing education credit!
1. [ ] A [ ] B [ ] C [ ] D [ ] E
2. [ ] A [ ] B [ ] C [ ] D
3. [ ] A [ ] B [ ] C [ ] D
4. [ ] A [ ] B [ ] C [ ] D [ ] E
5. [ ] A [ ] B [ ] C [ ] D [ ] E
6. [ ] A [ ] B [ ] C [ ] D
7. [ ] A [ ] B [ ] C [ ] D
8. [ ] A [ ] B [ ] C [ ] D
9. [ ] A [ ] B [ ] C [ ] D
10. [ ] A [ ] B [ ] C [ ] D [ ] E [ ] F
11. [ ] A [ ] B [ ] C [ ] D [ ] E [ ] F
12. [ ] A [ ] B [ ] C [ ] D [ ] E
To receive continuing education credit, you must
1. provide your contact information;
2. indicate your choice of CME, CEU, or CNE credit;
3. answer all of the test questions;
4. sign and date this form or a photocopy;
5. submit your answer form by April 27, 2003.
Failure to complete these items can result in a delay or rejection of
your application for continuing education credit.
13. [ ] A [ ] B [ ] C [ ] D [ ] E [ ] F
14. [ ] A [ ] B [ ] C [ ] D
15. [ ] A [ ] B [ ] C [ ] D [ ] E
16. [ ] A [ ] B [ ] C [ ] D [ ] E
17. [ ] A [ ] B [ ] C [ ] D [ ] E
18. [ ] A [ ] B [ ] C [ ] D [ ] E
19. [ ] A [ ] B [ ] C [ ] D [ ] E
20. [ ] A [ ] B [ ] C [ ] D [ ] E
21. [ ] A [ ] B [ ] C [ ] D [ ] E
22. [ ] A [ ] B [ ] C [ ] D [ ] E
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